$STEL

Stellar Bancorp, Inc. (STEL): Completion of Acquisition or Disposition of Assets

Stellar Bancorp, Inc. (STEL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0001473844 --12-31 0001473844 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): J

Original reporting
Published Jul 1, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 11:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$STEL
Neutral
high confidence
Mentioned
$STEL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STELNeutralMed
01

Why it matters

For STEL holders and merger-arb participants, the key new information is deal consummation plus the concrete payout terms and the planned NYSE withdrawal/suspension, which can quickly change tradability and spread dynamics.

02

Market read

STEL’s merger close and NYSE delisting request are actionable for merger-arb and liquidity/position management, with specified consideration terms.

03

What to watch

Traders should focus on post-close trading mechanics (expected cessation/liquidity) and how consideration (stock vs cash) may affect relative value versus any remaining arb spread.

Relevance 7/10Novelty 7/10Timing: as of July 1, 2026 (post-close) with NYSE suspension/withdrawal and STEL delisting actions.

Background

The filing is an SEC Form 8-K reporting completion of Stellar’s merger into Prosperity, including the exchange ratio and cash consideration, plus NYSE delisting steps.

Company-level read

Ticker impact

$STELNeutralHigh confidence
Context

Stellar Bancorp completed its merger into Prosperity Bancshares on July 1, 2026, with Stellar shares converted to Prosperity stock plus $11.36 cash.

Expected impact

Near-term STEL liquidity/price discovery likely deteriorates into delisting; merger consideration should dominate any remaining trading until cessation.

Evidence & confidence

The 8-K states the merger closed, specifies the exchange ratio and per-share cash consideration, and confirms NYSE withdrawal/suspension ahead of July 1, 2026.

Market effects

Bank M&A completion can shift regional bank consolidation expectations, but this filing is deal-mechanics focused rather than sector-wide guidance.

Potentially affects Texas banking market structure via Prosperity Bank becoming the surviving bank in the combined entity.

Limited global relevance; primarily a US regional banking consolidation event.

Counterpoint

Because the merger is already consummated, incremental price action in STEL may be muted versus earlier rumor/approval phases; most repricing may have occurred before close.

Key entities

  • Stellar Bancorp, Inc.

    Subject of the 8-K; merged into Prosperity Bancshares on July 1, 2026 and is being delisted from the NYSE.

  • Prosperity Bancshares, Inc.

    Surviving corporation in the merger; continues as the issuer whose common stock is received by Stellar shareholders.

  • Stellar Bank

    Wholly owned subsidiary of Stellar that merged into Prosperity Bank as part of the transactions.

  • Prosperity Bank

    Surviving bank entity in the bank-merger step.

Related articles

$BKUMed

Regional Banks Stocks Q1 Results: Benchmarking OFG Bancorp (NYSE:OFG)

The article benchmarks Q1 results for regional banks. BankUnited (BKU) reported $273.8M revenue (+6.1% YoY), missing analysts’ expectations by 5.1%, and also fell short on net interest income; shares were flat at $46.65. M&T Bank (MTB) posted $2.45B revenue (+5.9%), beating by 0.6% but missing tangible book value per share and net interest income; stock down 2.5% to $215.02. Stellar Bancorp (STEL) reported $111.2M revenue (+6%), beating by 2.5% and topping net interest income estimates; shares f

$JAZZHighAI 9/10

Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet

Jazz Pharmaceuticals (JAZZ) acquired Actio Biosciences for $820M, adding epilepsy drug ABS-1230 to its pipeline. Jazz reported record Q2 revenue of $1.2B and raised 2026 guidance to $4.6B-$4.75B. The deal adds to existing debt, and ABS-1230 is in early clinical stages. Jazz's shares trade at a forward P/E of 11.03.

$XBIOMed

Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition

Xenetic Biosciences (XBIO) agreed to acquire Santersus AG in an all-stock deal, pending shareholder approval. The combined company will rebrand as Santersus Bio, Inc. and trade under SNTS. The merger focuses on neutrophil extracellular traps (NETs) for treating various diseases, with four clinical programs planned. XBIO shares fell 40.98% to $2.52 on Wednesday, according to Benzinga Pro.

$CLMedAI 8/10

Colgate-Palmolive Explores Sale Of Softsoap, Irish Spring, Speed Stick Brands: Report

Colgate-Palmolive (CL) is exploring the sale of brands like Softsoap, Irish Spring, and Speed Stick, potentially fetching over $1 billion. The company is working with Goldman Sachs (GS) on the divestiture. Personal care accounted for 17% of CL's 2025 net sales, which totaled $20.38 billion. The move is part of a broader productivity and restructuring program aimed at generating annual pre-tax savings of $200 million to $300 million by 2028.